Bicara Therapeutics Inc. Common Stock Total Assets
Bicara Therapeutics Inc. Common Stock total assets. Based on the latest financial reports, Bicara Therapeutics Inc. Common Stock (BCAX) holds total assets worth $512.24 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see BCAX stock market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Bicara Therapeutics Inc. Common Stock (2022–2025)
Total assets of Bicara Therapeutics Inc. Common Stock from 2022 to 2025. This chart illustrates how Bicara Therapeutics Inc. Common Stock's total assets have evolved over time, based on quarterly financial data. See current stock price of Bicara Therapeutics Inc. Common Stock for real-time trading data and today's change.
Bicara Therapeutics Inc. Common Stock - Asset Composition Analysis
Bicara Therapeutics Inc. Common Stock Total Assets Breakdown (December 2025)
Bicara Therapeutics Inc. Common Stock total assets breakdown as of December 2025. Bicara Therapeutics Inc. Common Stock's total assets of $512.24 Million consist of 97.9% current assets and 2.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 22.4% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2022–2025)
This chart illustrates how Bicara Therapeutics Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore BCAX working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Bicara Therapeutics Inc. Common Stock's current assets represent 97.9% of total assets in 2025, an increase from 74.4% in 2022.
- Cash Position: Cash and equivalents constituted 22.4% of total assets in 2025, down from 62.0% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2022.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Bicara Therapeutics Inc. Common Stock Competitors by Total Assets
Key competitors of Bicara Therapeutics Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Bicara Therapeutics Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 11.59 | 25.80 | 15.32 |
| Quick Ratio | 11.59 | 25.80 | 15.32 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $460.35 Million | $427.16 Million | $215.99 Million |
Bicara Therapeutics Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Bicara Therapeutics Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.35 |
| Latest Market Cap to Assets Ratio | 1.38 |
| Asset Growth Rate (YoY) | -24.3% |
| Total Assets | $430.99 Million |
| Market Capitalization | $592.91 Million USD |
Valuation Analysis
Above Book Valuation: The market values Bicara Therapeutics Inc. Common Stock's assets above their book value (1.38x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Bicara Therapeutics Inc. Common Stock's assets decreased by 24.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Bicara Therapeutics Inc. Common Stock (2022–2025)
The table below shows the annual total assets of Bicara Therapeutics Inc. Common Stock from 2022 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $430.99 Million | -24.28% |
| 2024-12-31 | $569.20 Million | +143.26% |
| 2023-12-31 | $233.98 Million | +3390.71% |
| 2022-12-31 | $6.70 Million | -- |
About Bicara Therapeutics Inc. Common Stock
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was … Read more